|
2011/04/11
Shinichiro Akiyama1, Hiroyasu Yasuda2, Hiroyuki Abe1:
1Kudan Clinic, Tokyo, Japan,
2Tohoku Univ. School of Medicine, Yaotome Ekimae Clinic of Internal Medicine and Pediatrics, Sendai, Japan
Abstract
Background and objective: Tumor-specific cytotoxic T lymphocytes (CTLs) can be activated in vivo by dendritic cell (DC)-based
vaccination.
However, clinical responses to the immunotherapy with DC vaccination have only been observed in a minority of patients with
solid cancer.
In the current study, the clinical efficacy of the DC vaccine pulsed with the peptide derived from breast cancer-associated antigens
has been evaluated in the patients with advanced, inoperable breast cancer.
Patients and Methods: 21patients with advanced, inoperable breast cancer refractory to standard treatment were entered the study.
DCs which were generated from CD14+ monocytes from leukapheresis by 6-day cultivation with granulocyte macrophage-colony
stimulating factor (GM-CSF) and interleukin (IL)-4, were matured by OK-432, a streptococcal agent, and were pulsed with the
pancreatic cancer-associated antigens, such as WT1, MUC1. These DCs (1 x 107) were intradermally administered more than 5
times at 14-day intervals.
Results: Of the 21 patients, complete response (CR) was observed in 0 (0%), partial response (PR) in 2 (9.6%), stable disease
(SD) in 7 (33.3%), progressive disease (PD) in 12 (57.1%). Response rate was 9.6%.
Tumor control rate was 42.9%. Mean survival time after DC therapy was 514days. Severe side effects of more than grade 3 which
were assessed in accordance with NCI-Common Toxicity Criteria v.2.0, were not observed.
Conclusions: It was strongly suggested that the DC vaccination pulsed with cancer associated-peptides was safety and effective in
the patients with the inoperable breast cancer refractory to standard treatment.
• 2011 미국 암학회
April 4, 2011 Florida, USA
|
